| Line 456: | Line 456: | ||
==Mental Health - Depression== | ==Mental Health - Depression== | ||
===2018 [https://www.sciencedirect.com/science/article/abs/pii/S0149763417301793 Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression]=== | |||
*Nicotine improves cognitive performance in clinical and preclinical studies. | |||
*Nicotine may also benefit depressive symptoms and depressive behavior. | |||
*Cognitive and mood benefits may be mediated by nicotinic effect on neural networks. | |||
*Nicotine’s effects on networks may reverse network changes seen in depression. | |||
*Improvement to mood and cognition may particularly benefit older depressed adults. | |||
*Both preclinical and clinical studies support that nicotine and other nAChR agonists can improve depressive behavior, mood, and cognitive performance. nAChR agonists also demonstrate neuropharmacologic effects that oppose the intrinsic network alterations reported in MDD. Through modulation of intrinsic functional networks, nAChR agonists may reduce depressive symptoms, enhance emotional regulation ability, and improve cognitive deficits common in LLD. For these reasons, we propose nAChR agonists as a potential novel treatment for the mood and cognitive symptoms of LLD. | |||
*[https://sci-hub.st/10.1016/j.neubiorev.2017.08.018 PDF Version] | |||
*Citation: Gandelman, J. A., Newhouse, P., & Taylor, W. D. (2018). Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression. Neuroscience & Biobehavioral Reviews, 84, 289–298. doi:10.1016/j.neubiorev.2017.08.0 | |||
*Acknowledgement: Supported by NIH grants K24 MH110598 and CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences. | |||
edits